Literature DB >> 19956818

The role of opioids in managing chronic non-cancer pain.

Ban Leong Sng1, Stephan Alexander Schug.   

Abstract

The use of opioids for the treatment of chronic non-cancer pain has become more widespread recently. Available data support the short-term use of opioids in clearly defined nociceptive and neuropathic pain states. Their use in 'pathological' pain states without a clear diagnosis, such as chronic low back pain, is more contentious. A decision to initiate opioid treatment in these conditions requires careful consideration of benefits and risks; the latter include not only commonly considered adverse effects such as constipation, but also opioid-induced hyperalgesia, abuse, addiction and diversion. Ideally, treatment goals should not only be relief of pain, but also improvement of function. Opioid treatment of chronic non-cancer pain requires informed consent by, and preferably a treatment contract with, the patient. Treatment should be initiated by a trial period with defined endpoints using slow-release or transdermal opioids. Ongoing management of the patient requires ideally a multi-disciplinary setting. Treatment should not be regarded as life-long and can be discontinued by tapering the dose.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19956818

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  7 in total

1.  [Opioid therapy in patients with back pain. Claims data analysis for patient group characterization, influence on opioid therapy and work disability].

Authors:  A Höer; A Freytag; G Schiffhorst; S Schellhammer; M Thiede; G Glaeske; B Häussler
Journal:  Schmerz       Date:  2011-04       Impact factor: 1.107

2.  A policy-into-practice intervention to increase the uptake of evidence-based management of low back pain in primary care: a prospective cohort study.

Authors:  Helen Slater; Stephanie Joy Davies; Richard Parsons; John Louis Quintner; Stephan Alexander Schug
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

3.  Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence.

Authors:  Anne Z DePriest; Katie Miller
Journal:  Pain Ther       Date:  2014-05-06

4.  Synthesis, crystallographic characterization, molecular docking and biological activity of isoquinoline derivatives.

Authors:  Hatem A Abuelizz; Rashad Al-Salahi; Jamil Al-Asri; Jérémie Mortier; Mohamed Marzouk; Essam Ezzeldin; Azza A Ali; Mona G Khalil; Gerhard Wolber; Hazem A Ghabbour; Abdulrahman A Almehizia; Gehad A Abdel Jaleel
Journal:  Chem Cent J       Date:  2017-10-16       Impact factor: 4.215

5.  Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents.

Authors:  Eman A Ahmed; Mamdouh F A Mohamed; Omran A Omran
Journal:  RSC Adv       Date:  2022-09-05       Impact factor: 4.036

6.  Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids.

Authors:  Michael A Ueberall; Gerhard Hh Mueller-Schwefe
Journal:  J Pain Res       Date:  2015-08-10       Impact factor: 3.133

7.  Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.

Authors:  Richard Lawson; Frederic King; Kevin Marsh; Arman Altincatal; Ali Cimen
Journal:  Adv Ther       Date:  2016-06-24       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.